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ABSTRACT
Introduction: Sodium glucose co-transporter 2
(SGLT2) inhibitors increase urinary glucose
excretion (UGE) by reducing the renal threshold
for glucose excretion, which results in decreased
serum glucose concentrations in patients with
type 2 diabetes mellitus (T2D). However, no
study to date has determined whether larger
increases in UGE after SGLT2 inhibitor treat-
ment correspond to larger reductions in gly-
cated hemoglobin (HbA1C).
Methods: We enrolled participants who were
newly prescribed an SGLT2 inhibitor (da-
pagliflozin 10 mg or ipragliflozin 50 mg, once
daily) as an add-on therapy. Patients were tested
for HbA1C and first morning spot urinary-crea-
tinine and -glucose concentrations immediately
prior to administration of the SGLT2 inhibitor
and at a 12-week follow-up appointment. We
investigated the relationship between increases
in morning spot UGE and decreases in HbA1C.
Results: A total of 101 participants with T2D
were enrolled. The median age and diabetes
duration were 61.0 and 12.8 years, respectively,
and the median HbA1C was 8.10%. SGLT2
inhibitors significantly lowered the HbA1C level,
with a median change from baseline to week 12
of -0.60% (p\0.001). Robust increases from
baseline were seen for the morning spot urinary
glucose-to-creatinine ratio (UGCR), with a
median change at week 12 of 47.3 mg/mg. In
the correlation analysis, the DHbA1C level
showed a significant positive correlation with
Dmorning spot UGCR (r = 0.395, p\0.001). In
other words, a greater reduction in HbA1C was
correlated with a smaller increase in UGE. After
adjusting for confounding variables, DHbA1C
was significantly associated with Dmorning spot
UGCR.
Conclusions: Although SGLT2 inhibitor treat-
ment leads to a reduced HbA1C level by aug-
menting UGE, larger increases in UGE do not
correlate to larger reductions in HbA1C. This
suggests that the increase in UGE might not be
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an indicator of the degree of reductions in
blood glucose.
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INTRODUCTION
The renal threshold for glucose excretion (RTG)
is the serum glucose concentration at which
tubular reabsorption of glucose begins to satu-
rate and glucose first appears in the urine [1].
The cutoff values of RTG are dependent on
sodium glucose co-transporter 2 (SGLT2), which
is the protein responsible for the majority of
filtered glucose reabsorption from the proximal
renal tubules. Patients with type 2 diabetes
mellitus (T2D) have increased expression of
SGLT2 and elevated renal glucose absorption,
which may contribute to persistent hyper-
glycemia [2]. The advent of SGLT2 inhibitors,
which prevent glucose reabsorption from the
proximal renal tubules, thereby promoting uri-
nary glucose excretion (UGE) and decreasing
the serum glucose level, adds to the wide range
of pharmacotherapeutic options for treating
patients with diabetes [3].
In previous studies [4, 5], it was shown that
an SGLT2 inhibitor reduces RTG, increases UGE,
and decreases the serum glucose concentration
in patients with T2D. Increases in UGE, along
with improvements in blood glucose indices,
have been deemed pharmacological effects of
SGLT2 inhibitors. Furthermore, in multi-
ple-dose clinical studies of both healthy subjects
and patients with diabetes, SGLT2 inhibitors
dose-dependently decreased RTG, leading to a
dose-dependent increase in UGE [4–9]. How-
ever, there are no studies to date as to whether
larger increases in UGE after SGLT2 inhibitor
treatment translate to larger reductions in gly-
cated hemoglobin (HbA1c).
In this study, we aimed to investigate the
relationship between increases in morning spot
UGE, which showed good agreement with
overnight 8-h UGE in a previous study [10], and
decreases in HbA1C in patients with T2D after
SGLT2 inhibitor treatment.
METHODS
Study Participants
This was a retrospective, longitudinal study of
the patients with T2D who presented to Sever-
ance Hospital Diabetes Center between January
2015 and October 2016 and who were newly
prescribed an SGLT2 inhibitor (dapagliflozin
10 mg or ipragliflozin 50 mg, once daily) as an
add-on therapy to lower inadequately con-
trolled serum glucose. We enrolled participants
who had been tested for blood glucose param-
eters, including serum fasting glucose and
HbA1C, and first morning spot urinary crea-
tinine and glucose concentrations immediately
prior to the administration of the SGLT2 inhi-
bitor and at a 12-week follow-up visit. We used
the following inclusion criteria: (1) patients
who regularly visit the outpatient clinic for
blood glucose control and (2) patients who were
newly prescribed an SGLT2 inhibitor (da-
pagliflozin 10 mg or ipragliflozin 50 mg, once
daily) as an add-on therapy. Participants who
met the following criteria were excluded: (1)
\20 years of age; (2) type 1 diabetes; (3) preg-
nant women; (4) active infectious disease
including urinary tract infection; (5) estimated
glomerular filtration rate (eGFR) \60 ml/min/
1.73 m2.
Age, sex, weight, height, waist circumfer-
ence, blood pressure, duration of diabetes, and
pre-existing use of oral hypoglycemic agents or
insulin were recorded. Body mass index (BMI)
was calculated as weight divided by height
squared (kg/m2).
Compliance with Ethics Guidelines
All procedures performed in this study involv-
ing human participants were in accordance
with the ethical standards of the institutional
and/or national research committee and the
1964 Helsinki Declaration and its later amend-
ments or comparable ethical standards. The
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Institutional Review Board at Severance Hospi-
tal approved this study protocol (4-2016-0998).
Written informed consent for this study was not
required by the Institutional Review Board
because the database was only accessed for
analysis purposes and personal information was
not used.
Measurements of Blood and Urinary
Gluco-Metabolic Parameters
To exclude external factors such as food intake
on glucose homeostasis, participants were
advised to keep fasting after dinner, but could
drink water. Following an overnight fast, blood
tests for glucose, HbA1C, lipid profiles, and cre-
atinine were performed, and a routine fasting
morning urine sample was collected, both
immediately prior to the administration of the
SGLT2 inhibitor and at a 12-week follow-up
visit. The morning urine and blood were sam-
pled on the same day. In our previous study
[10], we determined that the overnight 8-h
UGE, overnight 8-h urinary glucose-to-crea-
tinine ratio (UGCR), and morning spot UGCR
showed good agreement with each other, sug-
gesting that morning spot UGCR can be used as
a simple index for estimating overnight
amounts of UGE in patients with T2D. HbA1C
was measured by an immunoassay using an
Integra 800 CTS (Roche, Hercules, CA, USA).
Serum glucose and creatinine were measured
using the Hitachi 7600 analyzer (Hitachi Ltd.,
Tokyo, Japan). For serum creatinine, a com-
pensated kinetic Jaffe´ method (Clinimate CRE,
Sekisui Medical Co., Ltd., Tokyo, Japan) was
used in which the creatinine concentration was
standardized to isotope dilution-mass spec-
trometry. The eGFR was derived using the
guidelines from the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) [11].
The urinary glucose levels were measured using
the hexokinase method with an AU680 chem-
istry analyzer (Beckman Coulter, Brea, CA,
USA). The urinary creatinine levels were mea-
sured using the AU680 analyzer (Beckman
Coulter, Inc.) with the kinetic Jaffe´ method.
Urinary glucose levels were expressed as UGCR
to minimize the influence of variations of
kidney function using the following formula:
morning spot UGCR (mg/mg) = [first-voided
morning spot urine glucose (mg/dl)/first-voided
morning spot urine creatinine (mg/dl)].
Statistical Analysis
All statistical analyses were performed using
SPSS version 23.0 for Windows (IBM Corp.,
Armonk, NY, USA). A normality test was per-
formed for all continuous variables. The data
are presented as mean ± standard deviation
(SD) for normally distributed continuous vari-
ables and as median (interquartile range) for
non-normally distributed continuous variables.
Categorical data are expressed as numbers and
percentages. The characteristics of the study
participants were analyzed according to the
change in HbA1C after 12 weeks of SGLT2 inhi-
bitor treatment using the two-sample Student’s
t test or the Mann-Whitney U test for continu-
ous variables and Pearson’s v2 test for categori-
cal variables. The laboratory parameters at
baseline and at week 12 of SGLT2 inhibitor
treatment were compared using a paired t test or
the Wilcoxon signed-rank test. The changes of
the major parameters from baseline to 12 weeks
were defined as follows: DHbA1C (%) = [HbA1C
at week 12 (%)—HbA1C at baseline (%)];
Dmorning spot UGCR (mg/mg) = [morning
spot UGCR at week 12 (mg/mg)—morning spot
UGCR at baseline (mg/mg)]. Correlations
between Dmorning spot UGCR and either
baseline HbA1C or DHbA1C were analyzed using
Spearman’s correlation coefficient. Multiple
linear regression analyses were performed on
logarithm-transformed values of Dmorning spot
UGCR to model the relationship between the
change in urinary glycemic indices and meta-
bolic parameters including DHbA1C. All P values
\0.05 were considered statistically significant.
RESULTS
Characteristics of the Study Participants
A total of 101 participants were recruited in this
study. The demographics and laboratory
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Table 1 Baseline characteristics of the study participants according to change in HbA1C after 12 weeks of treatment with
SGLT2 inhibitors (N = 101)
Baseline characteristics Total
(N5 101)
Decreased
HbA1c
(N5 77)
Increased
HbA1c
(N5 24)
P
value
Demographics
Age (years) 61.0 (51.0–68.0) 58.0 (50.5–67.5) 64.0 (51.3–73.0) 0.133
Male Sex [n (%)] 50 (49.5) 37 (48.1) 13 (54.2) 0.601
BMI (kg/m2) 26.4 ± 3.66 26.6 ± 3.76 25.9 ± 3.31 0.433
Waist circumference (cm) 92.0 ± 9.47 92.2 ± 9.41 91.5 ± 9.89 0.789
Systolic blood pressure (mmHg) 125.5 (116.0–133.0) 126.0 (115.3–132.8) 124.5 (116.0–135.8) 0.910
Diastolic blood pressure (mmHg) 74.9 ± 9.75 74.9 ± 9.73 74.8 ± 9.99 0.992
Duration of diabetes (years) 12.8 (8.88–17.8) 11.8 (8.88-17.4) 16.8 (9.06–18.5) 0.322
Laboratory indices
HbA1C (%) 8.10 (7.55–9.05) 8.30 (7.60–9.45) 7.60 (6.63–8.05) <0.001
Fasting glucose (mg/dl) 150.0 (126.5–180.0) 155.0 (130.5–191.0) 136.5 (111.0–155.8) 0.013
Total cholesterol (mg/dl) 150.0 (126.0–175.0) 152.0 (132.0–179.0) 131.0 (113.5–156.8) 0.035
Triglyceride (mg/dl) 123.0 (83.3–167.0) 127.0 (89.0–174.0) 90.0 (61.0–157.0) 0.043
HDL cholesterol (mg/dl) 43.0 (37.0–52.0) 43.0 (37.0–52.0) 44.5 (36.5–54.8) 0.415
LDL cholesterol (mg/dl) 79.4 ± 38.6 81.3 ± 41.0 73.0 ± 28.9 0.373
BUN (mg/dl) 15.3 ± 3.95 15.2 ± 3.96 15.6 ± 3.98 0.635
Creatinine (mg/dl) 0.73 (0.59–0.87) 0.74 (0.59–0.88) 0.67 (0.60–0.85) 0.641
eGFR CKD-EPI (ml/min/1.73 m2) 97.1 ± 18.3 96.8 ± 17.6 98.1 ± 20.8 0.766
Urinary glycemic indices
Morning spot urine glucose (mg/dl) 22.0 (8.50–149.0) 24.0 (8.50–165.0) 16.0 (9.00–123.3) 0.655
Morning spot UGCR (mg/mg) 0.19 (0.08–1.36) 0.19 (0.08–1.51) 0.20 (0.08–1.37) 0.955
Antidiabetic drugs
Metformin [n (%)] 86 (85.1) 65 (84.4) 21 (87.5) [0.999
Sulfonylurea [n (%)] 52 (51.5) 38 (49.4) 14 (58.3) 0.490
DPP-IV inhibitor [n (%)] 48 (47.5) 36 (46.8) 12 (50.0) 0.818
Thiazolidinediones [n (%)] 9 (8.90) 4 (5.20) 5 (20.8) 0.033
a-Glucosidase inhibitors [n (%)] 11 (10.9) 7 (9.10) 4 (16.7) 0.286
Insulin [n (%)] 37 (36.6) 30 (39.0) 7 (29.2) 0.471
Continuous variables are described as mean ± SD for parametric variables and median (interquartile range) for nonpara-
metric variables
Bold denotes statistical signiﬁcance at P\0.05
HbA1C glycated hemoglobin, SGLT2 sodium-glucose co-transporter 2, BMI body mass index, HDL high-density
lipoprotein, LDL low-density lipoprotein, BUN blood urea nitrogen, eGFR estimated glomerular ﬁltration rate, CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration, UGCR urinary glucose-to-creatinine ratio, DPP-IV dipeptidyl pep-
tidase-IV, SD standard deviation
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characteristics of the participants are shown in
Table 1. The median age and duration of dia-
betes among the study participants were 61.0
and 12.8 years, respectively. The participants
were divided into two groups according to
whether HbA1C decreased (N = 77) or increased
(N = 24) after 12 weeks of treatment with
SGLT2 inhibitors. The median value of DHbA1C
[HbA1C at week 12 (%)—HbA1C at baseline (%)]
in the two groups was -0.90% and 0.75%,
respectively. There were no significant differ-
ences in age, sex, BMI, waist circumference,
blood pressures, or duration of diabetes between
the two groups. The proportions of participants
taking oral hypoglycemic agents (except thia-
zolidinediones) or insulin were similar between
the two groups. With respect to laboratory
indices, baseline HbA1C and serum fasting glu-
cose were significantly higher in the group with
decreased HbA1C than in the group with
increased HbA1C. In addition, the baseline
HbA1C level showed a significant negative cor-
relation with DHbA1C level (Fig. 1), which sug-
gests that patients with higher baseline HbA1C
have greater reductions of HbA1C after taking an
SGLT2 inhibitor. The eGFR values calculated
using the CKD-EPI equation did not signifi-
cantly differ between the two groups. Regarding
urinary glycemic indices, neither the morning
spot urine glucose concentration nor morning
spot UGCR differed significantly between the
two groups. In the group with increased HbA1C,
only one participant showed a slightly lower
morning spot UGCR value after SGLT2 inhibitor
treatment compared to baseline (Dmorning spot
UGCR = -0.70 mg/mg).
Changes in Laboratory Parameters
from Baseline to Week 12
Changes in laboratory parameters from baseline
to week 12 of SGLT2 inhibitor treatment are
shown in Table 2. SGLT2 inhibitors (i.e., dapa-
gliflozin or ipragliflozin) used as an add-on
therapy significantly lowered the HbA1C level,
with a median change from baseline to week 12
of -0.60% (p\0.001). Similar to HbA1C, serum
fasting glucose was also significantly decreased
at week 12 compared to the baseline values,
with a median change of -25.0 mg/dl
(p\0.001). There was no significant change in
the eGFR at week 12 compared to baseline.
Robust increases from baseline were seen for
both the morning spot urine glucose concen-
tration and morning spot UGCR, with median
changes at week 12 of 3837 mg/dl and 47.3 mg/
mg, respectively.
Correlations between Change in Urinary
Glycemic Indices and Change in HbA1C
Level
In the correlation analyses, the baseline HbA1C
level (Fig. 2a) showed a significant negative
correlation with Dmorning spot UGCR.
Regarding the DHbA1C level (Fig. 2b), it showed
a significant positive correlation with Dmorning
spot UGCR. In other words, larger reductions in
HbA1C were correlated with smaller increases in
UGE.
Multiple Linear Regression Analysis
for Factors Affecting Changes in Urinary
Glycemic Indices
To determine which factors predicted changes
in urinary glycemic indices after SGLT2
inhibitor treatment, we performed multiple
linear regression analyses (Table 3) using
Fig. 1 Correlation between baseline HbA1C and DHbA1C
(N = 101). DHbA1C (%) = [HbA1C at week 12 (%)—
HbA1C at baseline (%)]. HbA1C glycated hemoglobin
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log-transformed Dmorning spot UGCR as the
dependent variable. In the univariate model,
age and eGFR were significantly associated
with Dmorning spot UGCR. After adjusting for
age, sex, eGFR, baseline morning spot UGCR,
and DHbA1C, both eGFR and DHbA1C were
significantly associated with Dmorning spot
UGCR.
DISCUSSION
Despite numerous reports on the clinical effi-
cacy and safety of SGLT2 inhibitors, a debate
remains regarding the direct causality between
the pharmacologic efficacy of SGLT2 inhibitors
in UGE and their clinical effectiveness in low-
ering the glucose level as assessed by several
glycemic indices since few observational studies
based on routine care have been performed. We
hypothesized that the increased glucose excre-
tion into the urine might decrease glycemic
parameters, such as HbA1C or glycated albumin,
in the blood. Based on these hypotheses, this
study aimed to investigate the relationship
between increases in morning spot urine glu-
cose parameters and decreases in HbA1C in
patients with T2D after taking SGLT2 inhibitors.
In this retrospective, observational study of
SGLT2 inhibitors in Korean patients with poorly
controlled T2D, we demonstrated three main
findings. First, based on the increased urinary
glucose levels after starting SGLT2 inhibitor
therapy, the pharmacological mode of action of
SGLT2 inhibitors on renal tubules is intact and
active. Second, based on the HbA1C results, we
determined that, despite the pharmacological
activity of SGLT2 inhibitors, there are respon-
ders and non-responders among the subjects
with T2D. Third, based on the increased morn-
ing spot urine glucose parameters and decreased
HbA1C, the relation between morning spot
urine glucose parameters and HbA1C is not as
simple as hypothesized.
In previous studies [6, 8], SGLT2 inhibitors
induced sustained glycosuria and improve-
ments in blood glucose. In a study of the addi-
tion of dapagliflozin treatment for patients with
T2D that was inadequately controlled on
pioglitazone [8], the beneficial effects of dapa-
gliflozin on hyperglycemia were maintained for
almost 1 year and were consistent with a sus-
tained pharmacodynamic activity toward gly-
cosuria. Consistent with these previous reports,
our study participants also showed a significant
increase in morning spot UGCR, indicating that
controlled glycosuria was induced after
12 weeks of SGLT2 inhibitor treatment. How-
ever, of the 101 participants, 8 had negative
Dmorning spot UGCR values after SGLT2 inhi-
bitor treatment. This suggests that the glyco-
suria can be divided into two categories. The
first category is natural-overflow glycosuria,
where UGE is caused by elevated blood glucose
and glomerular-filtered glucose levels. The other
category is chemically induced glycosuria for
Table 2 Changes in laboratory parameters from baseline to week 12 (N = 101)
Baseline Week 12 P
HbA1C (%) 8.10 (7.55–9.05) 7.50 (7.05–8.25) <0.001
Fasting glucose (mg/dl) 150.0 (126.5–180.0) 125.0 (108.5–148.0) <0.001
eGFR CKD-EPI (ml/min/1.73 m2) 96.4 ± 17.3 95.9 ± 18.3 0.415
Morning spot urine glucose (mg/dl) 22.0 (8.50–149.0) 3859.0 (2581.0–5158.5) <0.001
Morning spot UGCR (mg/mg) 0.19 (0.08–1.36) 47.5 (30.6–66.3) <0.001
Continuous variables are described as mean ± SD for parametric variables and median (interquartile range) for nonpara-
metric variables
Bold denotes statistical signiﬁcance at P\0.05
HbA1C glycated hemoglobin, eGFR estimated glomerular ﬁltration rate, CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration, UGCR urinary glucose-to-creatinine ratio
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managing hyperglycemia using an SGLT2 inhi-
bitor. In this study, those eight patients who
had negative Dmorning spot UGCR values had
very high baseline HbA1C levels of more than
9.90% with mean 12.2% (Table S1 for details).
Therefore, we postulate that, in patients with
very high HbA1C levels, the initial total glyco-
suria (natural overflow plus chemically induced
glycosuria) might be more augmented by SGLT2
inhibitor treatment, resulting in decreased
serum glucose levels. After the stable state of
pharmacologic efficacy of SGLT2 inhibitor, the
decreased levels of serum glucose in turn
decreased the urinary glucose excretion. The net
degree of chemically induced glycosuria caused
by the SGLT2 inhibitors might be lower than
the initial natural-overflow glycosuria.
In multiple-dose clinical studies of SGLT2
inhibitors in both healthy subjects and patients
with diabetes, SGLT2 inhibitors provided
dose-dependent reductions in RTG and increases
in UGE [4–9]. A study comparing 50-, 100-, and
Fig. 2 Correlations between Dmorning spot UGCR and
baseline HbA1C (a) or DHbA1C (b) (N = 101). Dmorn-
ing spot UGCR (mg/mg) = [morning spot UGCR at
week 12 (mg/mg)—morning spot UGCR at baseline (mg/
mg)]; DHbA1C (%) = [HbA1C at week 12 (%)—HbA1C
at baseline (%)]. UGCR urinary glucose-to-creatinine ratio,
HbA1C glycated hemoglobin
Table 3 Multiple linear regression models for change in morning spot UGCR (N = 101)
Variables Univariate Multivariate
STD b P STD b P
DHbA1C (%) 0.177 0.098 0.269 0.007
Age (years) 20.308 0.003 0.000 0.999
Male sex -0.069 0.518 -0.045 0.633
eGFR CKD-EPI (ml/min/1.73 m2) 0.464 <0.001 0.501 0.001
Baseline morning spot UGCR (mg/mg) 0.024 0.820 -0.030 0.747
Logarithm-transformed values of Dmorning spot UGCR were used as the dependent variable
DHbA1C (%) = [HbA1C at week 12 (%)—HbA1C at baseline (%)]; Dmorning spot UGCR (mg/mg) = [morning spot
UGCR at week 12 (mg/mg)—morning spot UGCR at baseline (mg/mg)]
Bold denotes statistical signiﬁcance at P\0.05
UGCR urinary glucose-to-creatinine ratio, HbA1c glycated hemoglobin, eGFR estimated glomerular ﬁltration rate, CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration, STD standardized
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300-mg doses of canagliflozin showed that the
mean 24-h RTG values decreased in a dose-de-
pendent manner in T2D patients [9]. In healthy
euglycemic subjects, canagliflozin dose-depen-
dently decreased mean 24-h RTG and increased
mean 24-h UGE [7]. However, the association
between the dose of SGLT2 inhibitor and the
degree of improvement in blood glucose is not
consistent in previous studies. In a study of five
dapagliflozin doses in T2D patients [6], changes
in fasting serum glucose were dose-related;
however, there was little evidence of a dose
response for either postprandial glucose or
HbA1C level. In a study of canagliflozin as an
add-on to metformin treatment [5], reductions
in HbA1C and fasting serum glucose showed
dose-dependent patterns. However, no study to
date has determined whether larger increases in
UGE after SGLT2 inhibitor treatment correlate
with larger reductions in HbA1C. We hypothe-
sized that the increased UGE might cause
decreased glycemic parameters, such as HbA1C
or glycated albumin, in the blood. In the cor-
relation and regression analyses, unlike our
hypothesis, the DHbA1C level and Dmorning
spot UGCR showed significant positive correla-
tions. In other words, a larger reduction in
HbA1C was correlated with a smaller increase in
UGE. We postulate that the pharmacological
effects of SGLT2 inhibitors result in increases in
chemically induced UGE and improvements in
blood glucose, and these improved blood glu-
cose levels trigger less chemically induced UGE
and markedly decrease natural-overflow
glycosuria.
Our study has some potential limitations.
Because the cutoff point for maximum glucose
reabsorption in the renal tubules (maximal
reabsorptive capacity, TmG) is not abrupt [12],
assessing RTG was impossible in this study
design. Therefore, we could not demonstrate a
clear relationship between the plasma glucose
concentration and urinary glucose amount.
Also, we did not collect information about the
time, type, or last meal consumed by the par-
ticipants, which might have an influence on
UGCR and glucagon levels. When serum glu-
cose levels are decreasing during fasting state,
glucagon is secreted from pancreatic a-cells and
signals the liver or kidney to increase glucose
output through gluconeogenesis [13]. Further-
more, in subjects with diabetes, it was reported
that SGLT2 inhibitor increased endogenous
glucose and raised levels of the glucagon hor-
mone, which prompts the body to produce
glucose [14]. The participants in our study were
newly prescribed an SGLT2 inhibitor as an
add-on therapy, and preexisting oral hypo-
glycemic agents or insulin was maintained
throughout study period in each participant.
Therefore, improvement in blood glucose was
thought to be mainly caused by SGLT2 inhibitor
treatment. However, further studies are needed
to be investigated on the potential underlying
pathophysiology on urinary glucose homeosta-
sis and pharmacologic influences of SGLT2
inhibitors including glucagon levels and food
effects on UGCR in accurate research settings
for better management in T2D.
CONCLUSION
Although SGLT2 inhibitor treatment leads to
reduced HbA1C levels by augmenting UGE (i.e.,
medication efficacy), larger increases in UGE
after SGLT2 inhibitor treatment do not correlate
to larger reductions in HbA1C (i.e., effective-
ness). This suggests that the relation between
morning spot urine glucose parameters and
HbA1C is not as simple as hypothesized and
increases in UGE might not be an indicator of
the degree of reductions in blood glucose.
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